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Association Between HIV-1 Coreceptor Usage and
Resistance to Broadly Neutralizing Antibodies
Nico Pfeifer, Dr,* Hauke Walter, MD,† and Thomas Lengauer, Dr, PhD*
Background: Recently discovered broadly neutralizing antibodies
have revitalized hopes of developing a universal vaccine against
HIV-1. Mainly responsible for new infections are variants only using
CCR5 for cell entry, whereas CXCR4-using variants can become
dominant in later infection stages.
Methods: We performed a statistical analysis on two different
previously published data sets. The first data set was a panel of 199
diverse HIV-1 isolates for which IC50 neutralization titers were
determined for the broadly neutralizing antibodies VRC01, VRC-
PG04, PG9, and PG16. The second data set contained env sequences
of viral variants extracted from HIV-1–infected humanized mice
treated with the antibody PGT128 and from untreated control mice.
Results: For the panel of 199 diverse HIV-1 isolates, we found
a statistically significant association between viral resistance to PG9
and PG16 and CXCR4 coreceptor usage (P = 0.0011 and P =
0.0010, respectively). Our analysis of viral variants from HIV-1–
infected humanized mice under treatment with the broadly neutral-
izing antibody PGT128 indicated that certain antibodies might drive
a viral population toward developing CXCR4 coreceptor usage capa-
bility (P = 0.0011 for the comparison between PGT128 and control
measurement).
Conclusions: These analyses highlight the importance of account-
ing for a possible coreceptor usage bias pertaining to the effective-
ness of an HIV vaccine and to passive antibody transfer as
therapeutic approach.
Key Words: broadly neutralizing antibodies, HIV, vaccine, corecep-
tor tropism
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INTRODUCTION
With more than 2.5 million new HIV-1 infections each
year, there is an urgent need for additional protective
measures against this virus. A natural approach to preventing
HIV infections would be to vaccinate people with a universal
HIV vaccine. One alternative is to induce neutralizing anti-
bodies that interfere with the process of viral cell entry like
for hepatitis B vaccine. Unfortunately, because of the high
genomic diversity of HIV, a universal HIV vaccine that elicits
broad neutralization responses against most of the existing
HIV strains has not yet been discovered.1 Most recent ap-
proaches to isolate broadly neutralizing antibodies from
patient sera2–4 have demonstrated promising results. One of
these new antibodies, PG9, has been shown to interact with
the glycan shield and specific sites of the variable loops 1 and
2 as well as the variable loop 3 (V3)2,5 of the Env protein of
the virus. The structure of these loops largely determines
which coreceptor the virus can use for entering and infecting
new cells. The two coreceptors that are mainly relevant
in vivo are the chemokine receptors CCR5 and CXCR4. Vi-
ruses that can only bind to the CCR5 coreceptor are called R5
viruses, and viruses that can only use the CXCR4 coreceptor
are called X4 viruses. Generally, viruses capable of binding to
both coreceptors are called dual-tropic viruses, however, the
discrimination of dual-tropic and X4 viruses is difficult to
make both by genotypic and (commercially available) pheno-
typic assays. Here, we refer to X4-capable viruses for
both, X4 viruses and dual-tropic viruses. These have very
low capacity of newly infecting humans—at least by sexual
transmission—as evidenced by the highly significant under-
representation of individuals with a homozygous D32 variant
of the CCR5 structural gene among seropositive white indi-
viduals.6 These people lack a functional CCR5 coreceptor and
therefore cannot be infected by R5 viruses. The fact that only
very few individuals with this mutation were HIV seroposi-
tive as compared with the mutation frequency in the
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population indicates that R5 viruses might be more relevant
regarding new infections than X4-capable viruses. Thus,
a vaccine needs to elicit responses against R5 viruses, but
responses against X4-capable viruses are less important for
preventing HIV infection.
Beyond using knowledge about broadly neutralizing
antibodies for vaccine design, it might be possible to
effectively treat HIV-1–infected patients with a combination
of these antibodies. Klein et al7 showed that HIV-1–infected
humanized mice could be effectively treated by a combination
of broadly neutralizing antibodies and proposed to re-examine
this approach as a treatment modality in HIV-1–infected pa-
tients. Recent studies in SHIV-infected Rhesus macaques also
yielded promising results.8,9
In this work, we show that there is a significant
association between CXCR4 coreceptor usage and resistance
to PG9 and PG16.2 We provide evidence that this may have
important implications both for vaccination approaches and
for therapeutic approaches: The first implication is while con-
figuring a panel assessing neutralization capacities of anti-
bodies against HIV-1, one should take coreceptor usage of
the strains into account for an unbiased evaluation of an anti-
body’s capacity to neutralize strains that can establish an
infection. The second implication is that certain antibodies
such as PGT128, which was one of the antibodies Klein
et al7 used in their study, might drive the viral population
toward developing CXCR4 coreceptor usage capability. This
is supported by our analysis on data from their study showing
a significant difference between coreceptor usage of the var-
iants emerging under treatment with PGT128 as compared
with the control variants at similar time points. Treatment
with a combination of such antibodies might therefore be
problematic in patients with weak immune systems harboring
a substantially higher risk of carrying X4-capable viruses.10
Therefore, it seems advantageous to place similar restrictions
on treatment with neutralizing antibodies causing the selec-
tion of X4-capable viruses as those already in use for CCR5
antagonists. We suggest that this issue be investigated further
before testing these potent monoclonal antibodies in this
group of people.
MATERIALS AND METHODS
To investigate the association between coreceptor usage
and neutralization capabilities of specific broadly neutralizing
antibodies, we evaluated coreceptor usage on a large HIV-1
isolate panel introduced recently.11 In that study, the neutrali-
zation capabilities of the broadly neutralizing antibodies
VRC01, VRC-PG04, PG9, and PG16 were evaluated against
a panel of 208 different HIV isolates from different subtypes,
also including recombinant forms. Env sequences that covered
the V3 region were available for only 199 of the 208 strains
(see additional file 2, http://links.lww.com/QAI/A550). The
coreceptor usage of these 199 strains was determined with
the widely used prediction tool geno2pheno[coreceptor].
12 The
prediction model is based on the V3 sequence only and has
been shown to have good performance13 predicting both, phe-
notypic tropism and clinical response to treatment with R5
antagonists. geno2pheno[coreceptor] uses a linear support vector
machine to predict whether a sequence is from an X4-capable
or an R5 virus. The distance of the sequence to the separating
hyperplane is transformed into a false-positive rate (FPR) to
facilitate interpretability in terms of the confidence of the pre-
diction. geno2pheno[coreceptor] reports the minimal FPR at
which the sequence would be classified as X4-capable. In this
calculation, X4-capable viruses are considered positive sam-
ples and R5 viruses are considered negative samples. It is
general clinical practice to determine coreceptor usage based
on this notion of FPR and on expert knowledge. In Europe,
interpretation of tropism by geno2pheno[coreceptor] has been
included in the guidelines for determining HIV-1 coreceptor
tropism.14 We adhered to the 10% FPR cutoff to distinguish
X4-capable viruses from R5 viruses as recommended by the
European Consensus Group on clinical management of HIV-1
tropism testing.14 With the cutoffs of 5% and 15% as recom-
mended by the German treatment guidelines, we achieved
similar results. These guidelines suggest to classify all
viruses with an FPR of less than 5% as X4-capable and
all viruses with an FPR of 15% or more as R5 disregarding
the viruses with FPRs between 5% and 15%. The numbers
of sensitive and resistant strains, respectively, for the differ-
ent antibodies using the 5%/15% cutoffs are shown in the
Supplemental Digital Content (see Table S1, Supplemental
Digital Content, http://links.lww.com/QAI/A550).
For 15 of the 199 isolates from the test panel, tropism
information from biological experiments was available in the
Los Alamos HIV database (see Table S2, Supplemental
Digital Content, http://links.lww.com/QAI/A550). Using
the 10% FPR threshold for geno2pheno[coreceptor], 13 of 15
HIV variants are assigned the same tropism label. The two
discordances are for borderline cases (between 5% and 15%
FPR), but they do not change the numbers calculated from
data presented in Table 1 because both variants are resistant to
PG9/PG16 and tropisms are R5 and X4-capable, respectively.
Note that the analysis in the Supplemental Digital Content
does not include variants in the borderline region and still
TABLE 1. Coreceptor Usage of HIV Variants Resistant and
Susceptible to 4 Different Broadly Neutralizing Antibodies
Antibody X4-capable R5 P
VRC01
Resistant 2 18 0.3760
Sensitive 37 142 —
VRC-PG04
Resistant 6 33 0.6528
Sensitive 33 127 —
PG9
Resistant 17 28 0.0011
Sensitive 22 132 —
PG16
Resistant 19 34 0.0010
Sensitive 20 126
This table shows the number of resistant and sensitive strains with regard to their
coreceptor usage for VRC01, VRC-PG04, PG9, and PG16. Strains were considered
resistant to an antibody if the IC50 value was larger than 50 mg/mL and sensitive
otherwise.
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finds a similarly strong association between coreceptor tro-
pism and PG9/PG16 resistance (see Table S1, Supplemental
Digital Content, http://links.lww.com/QAI/A550).
To test whether the sensitivity/resistance to an antibody
or serum is significantly different with regard to viral tropism,
we computed P values using the two-sided Fisher exact test
for the two-by-two contingency tables with resistant/sensitive
as the row label and X4-capable/R5 as the column label using
significance level a = 0.05. The null hypothesis is that there is
no difference.
To investigate which amino acids at which position of the
Env protein are associated with PG9 sensitivity, we performed
the Fisher exact test for all observed amino-acid polymor-
phisms at all sequence locations. The q values were calculated
according to Storey and Tibshirani15 by conservatively assum-
ing p0 to be equal to 1. We performed the same analysis also
for finding associations between observed amino-acid polymor-
phisms and predicted coreceptor usage (with the 10% FPR
threshold introduced above).
To calculate the potential N-glycosylation sites, we
used the tool N-glycosite.16 The numbering of the positions
is according to the Env amino-acid sequence of the HIV
strain HXB2.
For comparing the effect of treatment by passive
antibody transfer with broadly neutralizing antibodies, we
computed the coreceptor usage FPR values for each variant of
each treatment using geno2pheno[coreceptor].
12 For each com-
parison between treatments (e.g., PGT128 versus 45-46GW),
we tested whether there is a significant difference between the
2 sets of FPRs according to a Wilcoxon rank-sum test at
a significance level of a = 0.05.
RESULTS AND DISCUSSION
Neutralization Capabilities of PG9 and PG16
Are Biased Toward R5 Viruses
The glycan shield of HIV-1 differs considerably between
R5 viruses and X4-capable viruses with fewer glycans being
attached to X4-capable viruses. Additionally, there are specific
sites in V3 that are highly predictive of coreceptor usage.
Therefore, we evaluated whether there is a significant differ-
ence between the viruses that can be neutralized by PG9
(sensitive strains) and viruses that cannot be neutralized by
PG9 (resistant strains) with regard to their coreceptor usage
(viral tropism) based on data from a recent neutralization
study.11 We found a statistically significant difference (P =
0.0011) between the sensitive and the resistant strains accord-
ing to the Fisher exact test, with a higher fraction of X4-
capable viruses in the group of resistant strains. This means
that a significantly higher percentage of HIV strains resistant to
PG9 are X4-capable than expected by chance. An analogous
analysis for the broadly neutralizing antibody PG16, which is
known to bind to variable loops 1 and 2 as well as to V3, led to
a similarly strong P value (0.0010). We call this property of an
antibody to neutralize R5 viruses more effectively than X4-
capable viruses R5-bias from now on. For comparison, the
same evaluation for the broadly neutralizing antibodies
VRC01 and VRC-PG04 that bind to the CD4 binding site
did not show a significant association (P = 0.3760 and P =
0.6528, respectively). The exact numbers are given in Table 1.
Only 56% and 51%, respectively, of X4-capable viruses could
be neutralized by PG9 and PG16, compared with 95% and
85%, respectively, of X4-capable viruses that could be neutral-
ized by VRC01 and VRC-PG04. This implies that the higher
the fraction of X4-capable viruses in the panel, the worse will
antibodies with an R5-bias perform, unless coreceptor usage of
the viral strains is taken into account. Analyzing only R5-tropic
strains, the percentage of strains sensitive to PG9 increased
from 77% to 83% and from 73% to 79% for PG16, whereas
it remained at similar levels for VRC01 (89% instead of 90%)
and VRC-PG04 (80% for both evaluations). Therefore, when
evaluating the breadth of antibodies with regard to preventing
new HIV infections, the coreceptor usage of the viruses should
be taken into account. Because R5 viruses are driving primary
HIV infections almost exclusively, the unknown use of
X4-capable viruses in a panel may lead to underestimation of
the breadth of neutralizing capacities of R5-biased antibodies.
Positions in the V3 Loop Are Predictive of
PG9 Resistance
Additionally, we investigated whether certain amino
acids at specific positions of the Env protein are associated
with sensitivity/resistance to PG9 as described in the Methods
section. The most significant association was observed
between an asparagine at position 160 of the Gp120 protein
(P = 1.90e210) and PG9 sensitivity. This association is sup-
ported by a recent structural analysis by McLellan et al,5
which found that the N-linked glycan at position 160 is crit-
ical for PG9 recognition. They also hypothesized that
N-linked glycans at positions 156 and 173 are important for
PG9 recognition. The frequencies of potential N-linked gly-
cosylation sites (PNG) among sensitive and resistant viruses,
respectively, for the region between positions 152 and 173 are
shown in Figure 1. All sensitive viruses had a PNG at position
160, whereas only about 62% of the PG9-resistant viruses
possessed a PNG at that position. There was no significant
difference between PNG frequencies at positions 156 and 173
for sensitive and resistant viruses. The association analysis on
the complete Env protein sequence resulted in 4 associations
that were significant after correction for multiple testing (q ,
0.05). Additional to the asparagine at position 160, we found
a lysine at position 432 (P = 8.27e206), a valine at position
372 (P = 1.38e205), and a glutamine at position 315 (P =
2.07e205) to be significantly associated with PG9 sensitivity/
resistance. This supports the hypothesis that more positions
than just the ones responsible for the glycan interaction are
important for determining sensitivity to PG9. Furthermore,
there were 27 PG9-resistant viruses in the panel, for which
the PNGs at position 160 and either at position 156 or at
position 173 could be observed. This underlines that
viruses can be resistant to PG9 although they possess the
N-glycosylation sites important for PG9 binding discovered
by McLellan et al.5 Another association, a threonine at posi-
tion 319 with P value of 0.0001 came out just slightly above
the q value threshold (q value = 0.055). Positions 315 and 319
are located in the V3 region of HIV and are highly predictive
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of coreceptor usage (arginine at position 315: P = 2.80e205;
and alanine at position 319: P = 1.74e208). This supports the
hypothesis that there is a relation between PG9 sensitivity and
coreceptor usage. A similar but slightly weaker association
could be observed for PG16 shown in the Supplemental Dig-
ital Content (see Appendix S1, Supplemental Digital
Content, http://links.lww.com/QAI/A550).
PGT Antibodies Might Have an Even Stronger
R5-Bias and Could Drive HIV Variants Toward
Developing CXCR4-Usage Capability
It has been shown that the highly potent PGT-
neutralizing antibodies interact with V3 sites 323, 324, 325,
and 327 as well as N-linked glycans at position 301 and/or
332.17,18 Thus, these antibodies might also exhibit stronger
neutralization capabilities against R5 viruses than against
X4-capable viruses. In previous studies, many of these anti-
bodies (e.g., PGT128 and PGT121) were almost 10-fold more
potent than PG9, PG16, and VRC01, but their neutralization
capabilities were less broad. Unfortunately, Walker et al17 do
not provide the env sequences from the test panel, which is why
we could not predict coreceptor usage for the test panel they
used. However, we could test for an R5-bias on neutralization
data from sera of patients of the CAPRISA Acute Infection
study with PGT-like neutralization potential.19 For one of the
sera, the authors showed computationally and through a muta-
tion study that position 316 was highly relevant for neutraliza-
tion. This was the only serum for which they showed that there
was an important position in the V3 loop. We tested whether
there is a significant difference between the viruses that can be
neutralized by CAP8 serum (sensitive strains) and viruses that
cannot be neutralized by CAP8 serum (resistant strains) with
regard to their coreceptor usage (viral tropism) as described in
the Methods section and found a significant difference (P =
0.013). The counts can be found in Table 2. The P value is
slightly larger than the P values for the tests between PG9/
PG16 resistance and viral tropism described above, but this
might be due to the use of whole sera to test the neutralization
capability instead of monoclonal antibodies. Likely, some of
the sera used contain antibodies with an R5-bias and additional
antibodies that are able to neutralize X4-capable viruses reduc-
ing in the overall R5-bias of the serum. One could also test for
the effect of PGT121 using the test panel of Mouquet et al20;
but because the number of viruses in this panel is 119 com-
pared with 208 and 225 in the other two panels, it could be that
the sample size is too small to reach significance.
Additionally, we could test whether PGT128 exhibits
R5-bias on data from Klein et al.7 In their study, the research-
ers monitored HIV-infected humanized mice that were under
treatment with broadly neutralizing antibodies for several
weeks. This monitoring included the sequencing of the viral
populations at various time points (between 6 and 80 days
after beginning of treatment). Because all mice were infected
with the same HIV variant, we could test whether there was
a significant difference in the coreceptor usage of the variants
emerging after beginning of treatment as described in the
Methods section. When comparing PGT128 with 45-46GW,
which is an antibody that binds to the CD4 binding site, we
found a significant difference (P = 0.0008) with a trend
toward CXCR4-usage for the variants extracted from the mice
treated with PGT128. A similar result could be found for the
comparison between PGT128 and the control measurement
(P = 0.0011). The basis for this analysis were the V3 loop
FIGURE 1. Differences in glycosylation between
HIV strains that are sensitive and resistant to PG9,
respectively. All viruses sensitive to PG9 had a PNG
at position 160 (black), whereas this was not the
case for viruses resistant to PG9 (gray).
TABLE 2. Coreceptor Usage of HIV Variants Resistant and
Sensitive to CAP8 Serum According to the 10% FPR Cutoff
Antibody X4-capable R5 P
CAP8 serum
Resistant 7 13 0.013
Sensitive 23 165 —
This table shows the number of resistant and sensitive HIV variants with regard to
their coreceptor usage for serum CAP8 from the CAPRISA Acute Infection study.19
Variants were considered sensitive to the serum if the ID50 value was larger than 20 and
sensitive otherwise.19
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sequences of 32, 84, and 66 HIV variants extracted from
the PGT128-treated mice, the 45-46GW-treated mice, and
the control mice, respectively. For the mice treated with the
penta-mix that also contained PGT128, we could not find
a similar trend, but this might be due to the lower viral load
of these mice throughout the course of treatment indicating
a higher antiviral efficacy of the combined antibody treat-
ment. Note that PGT128 was not contained in the tri-mix that
Klein et al. tested.
We could not find a significant difference between
treatment with PG16 and treatment with 45-46GW (also not
compared with the control measurements). This may be
due to the lower antiviral efficacy of PG16 in comparison
with PGT12817 resulting in a lower selective pressure, such
that the time interval of treatment was too short for escape
variants to emerge. Alternatively, the R5-bias itself might be
stronger for PGT128 than for PG16. This hypothesis deserves
further investigation.
CONCLUSION
We have shown that PG9 and PG16 neutralize a sub-
stantially higher percentage of strains when excluding
X4-capable viruses, whereas there is no such effect for the
CD4-binding site antibodies VRC01 and VRC-PG04. Addi-
tionally, we could show that certain amino acids at specific
positions of the Env protein are significantly associated with
PG9 sensitivity/resistance. We observed the already known
relevance of the amino acid asparagine at position 160 in this
context, but we also discovered previously unknown associ-
ations. Some of these amino-acid variants are also signifi-
cantly associated with coreceptor usage, supporting the
hypothesis that resistance to the broadly neutralizing antibod-
ies PG9 and PG16 can be associated with coreceptor usage.
Because neutralization of X4-capable viruses is less important
for preventing new infections, further HIV vaccine studies
should account for coreceptor usage of the viral populations
in the target isolates, to avoid underestimating the power of
R5-biased broadly neutralizing antibodies in this setting. It
would also be worth evaluating whether there are antibodies
with a bias against HIV variants harboring other properties
related to be more or less relevant in HIV primary infection,
such as low-level monocyte-derived macrophages replication,
because enhanced monocyte-derived macrophage replication
is related to mortality among infected patients.21
It has to be noted that our coreceptor assignments were
based on predictions of the tool geno2pheno[coreceptor]
12
instead of phenotypic assays such as Trofile or ESTA.22
Genotypic coreceptor usage tests are general practice in sev-
eral regions of the world for the determination of viral tro-
pism. For Europe, Sanger sequencing of the V3 loop in
combination with geno2pheno[coreceptor] was included into
the guidelines for HIV-1 coreceptor tropism determination,14
underlining the confidence in this method. In recent reanaly-
ses of the early maraviroc clinical trials, genotypic methods
were at least as clinically predictive as Trofile.23 Finally, for
sequences of the panel for which phenotypic information is
available from biological experiments, there was a high agree-
ment between the phenotypic assay and the bioinformatic
prediction method (see Table S2, Supplemental Digital
Content, http://links.lww.com/QAI/A550).
It has been shown recently that viral escape from glycan-
dependent broadly neutralizing antibodies can lead to changes
in glycosylation patterns of HIV.24 We have shown in our
analysis that PGT128 might drive the HIV population of in-
fected individuals faster toward developing CXCR4 coreceptor
usage capability. It can be expected that similar antibodies to
PGT128 have a comparable effect. Of note, there is no clear
evidence to believe that X4-capable viruses induced by an R5
virus-blocking treatment are causing faster disease progression.
A careful strategy would be either to exclude antibodies with
an R5-bias from or to include an antibody with good neutral-
ization capabilities against X4 viruses into antibody treatment
combinations to reduce the chance of a coreceptor switch. This
might not be necessary in pre-exposure prophylaxis settings,
where it can be expected that enhancing the immune system’s
capability of neutralizing R5 viruses is much more important
than supporting the neutralization of X4-capable viruses.25
Furthermore, the finding that PGT128 can drive
coreceptor switch adds to the discussion about why certain
HIV-infected patients never develop X4-capable viruses. It
could be that a certain antibody response against parts of the
V3 loop is necessary for a coreceptor switch or at least makes
it more likely.
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